Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: A meta-analysis

European Journal of Heart Failure

Volumn 16, Issue 4, 2014, Pages 444-453

  Wu, Xiaojing ^a   Yang, Te ^a   Zhou, Qi ^b   Li, Shuangfei ^a   Huang, Lan ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Chronic heart failure; Left heart disease; Meta analysis; Phosphodiesterase type 5 inhibitor; Pulmonary hypertension

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; SILDENAFIL; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONAMIDE;

ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE DISORDER; CARDIOVASCULAR PARAMETERS; CHRONIC DISEASE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EMOTIONALITY; EXERCISE; FATIGUE; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART VENTRICLE TACHYCARDIA; HOSPITAL ADMISSION; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; META ANALYSIS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTOLIC HEART FAILURE; TREATMENT RESPONSE; COMPLICATION; DRUG EFFECTS; EXERCISE TOLERANCE; HYPERTENSION, PULMONARY; PATHOPHYSIOLOGY; PHYSIOLOGY;

BLOOD PRESSURE; EXERCISE TOLERANCE; HEART FAILURE, SYSTOLIC; HEART RATE; HUMANS; HYPERTENSION, PULMONARY; OXYGEN CONSUMPTION; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; QUALITY OF LIFE; SULFONAMIDES;

EID: 84937557860     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.47     Document Type: Article

References (46)

1. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L,. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001; 37: 183-188.
2. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM,. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009; 53: 1119-1126.
3. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
4. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE, Darius H, Schulman K, Zannad F, Handberg-Thurmond E, Harrell FE Jr, Wheeler W, Soler-Soler J, Swedberg K,. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134: 44-54.
5. Rubin LJ,. Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT. Circulation 2013; 128: 475-476.
6. Stuart D, Chapman M, Rees S, Woodward S, Kohan DE,. Myocardial, smooth muscle, nephron, and collecting duct gene targeting reveals the organ sites of endothelin A receptor antagonist fluid retention. J Pharmacol Exp Ther 2013; 346: 182-189.
7. Barton M, Kohan DE,. Endothelin antagonists in clinical trials: lessons learned. Contrib Nephrol 2011; 172: 255-260.
8. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Lüscher TF, EARTH investigators. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 347-354.
9. Kukreja RC, Salloum FN, Das A,. Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. J Am Coll Cardiol 2012; 59: 1921-1927.
10. Dumitrescu D, Seck C, Möhle L, Erdmann E, Rosenkranz S,. Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension. Int J Cardiol 2012; 154: 205-206.
11. Reichenbach A, Al-Hiti H, Malek I, Pirk J, Goncalvesova E, Kautzner J, Melenovsky V,. The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: a case-control study. Int J Cardiol 2013; 168: 60-65.
12. Lindman BR, Zajarias A, Madrazo JA, Shah J, Gage BF, Novak E, Johnson SN, Chakinala MM, Hohn TA, Saghir M, Mann DL,. Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis. Circulation 2012; 125: 2353-2362.
13. Botha P, Parry G, Dark JH, Macgowan GA,. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. J Heart Lung Transplant 2009; 28: 676-682.
14. Guazzi M, Vicenzi M, Arena R,. Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. Eur J Heart Fail 2012; 14: 82-90.
15. Guazzi M, Vicenzi M, Arena R, Guazzi MD,. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011; 4: 8-17.
16. Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N,. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 2008; 14: 189-197.
17. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ,. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116: 1555-1562.
18. Lewis GD, Shah RV, Pappagianopolas PP, Systrom DM, Semigran MJ,. Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone. Circ Heart Fail 2008; 1: 227-233.
19. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD,. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50: 2136-2144.
20. Guazzi M, Vicenzi M, Arena R, Guazzi MD,. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011; 124: 164-174.
21. Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, Hillege HL, van Veldhuisen DJ, van Gilst WH,. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 2013; 34: 1424-1431.
22. Borgdorff MA, Bartelds B, Dickinson MG, Boersma B, Weij M, Zandvoort A, Silljé HH, Steendijk P, de Vroomen M, Berger RM,. Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle. Eur J Heart Fail 2012; 14: 1067-1074.
23. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB,. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23: 685-713.
24. Guyatt GH, Nogradi S, Halcrow S, Singer J, Sullivan MJ, Fallen EL,. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med 1989; 4: 101-107.
25. Rosenkranz S, Bonderman D, Buerke M, Felgendreher R, ten Freyhaus H, Grünig E, de Haan F, Hammerstingl C, Harreuter A, Hohenforst-Schmidt W, Kindermann I, Kindermann M, Kleber FX, Kuckeland M, Kuebler WM, Mertens D, Mitrovic V, Opitz C, Schmeisser A, Schulz U, Speich R, Zeh W, Weil J,. Pulmonary hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2011; 154: S34-S44.
26. Cockrill BA, Waxman AB,. Phosphodiesterase-5 inhibitors. Handb Exp Pharmacol 2013; 218: 229-255.
27. Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G, Fassett J, Tao Y, Zhang P, dos Remedios C, Pritzker M, Hall JL, Garry DJ, Chen Y,. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation 2010; 121: 1474-1483.
28. Salloum FN, Abbate A, Das A, Houser JE, Mudrick CA, Qureshi IZ, Hoke NN, Roy SK, Brown WR, Prabhakar S, Kukreja RC,. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 2008; 294: H1398-H1406.
29. Hryniewicz K, Dimayuga C, Hudaihed A, Androne AS, Zheng H, Jankowski K, Katz SD,. Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci (Lond) 2005; 108: 331-338.
30. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA,. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11: 214-222.
31. Stehlik J, Movsesian MA,. Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure. Expert Opin Investig Drugs 2006; 15: 733-742.
32. Kass DA,. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3? Circulation 2007; 116: 233-235.
33. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL,. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-1475.
34. Chaumais MC, Perrin S, Sitbon O, Simonneau G, Humbert M, Montani D,. Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. Expert Opin Drug Metab Toxicol 2013; 9: 1193-1205.
35. Ding B, Abe J, Wei H, Huang Q, Walsh RA, Molina CA, Zhao A, Sadoshima J, Blaxall BC, Berk BC, Yan C,. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 2005; 111: 2469-2476.
36. Ding B, Abe J, Wei H, Xu H, Che W, Aizawa T, Liu W, Molina CA, Sadoshima J, Blaxall BC, Berk BC, Yan C,. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci USA 2005; 102: 14771-14776.
37. Nishio R, Tanaka H, Tsuboi Y, Kinutani H, Taniguchi Y, Shigeru M, Toh R, Miura Y, Sakai Y, Emoto N, Kawai H, Hirata K,. Differences in hemodynamic parameters and exercise capacity between patients with pulmonary arterial hypertension and chronic heart failure. J Cardiopulm Rehabil Prev 2012; 32: 379-385.
38. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR,. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83: 778-786.
39. Bocchi EA, Auler JO Jr, Guimarães GV, Carmona MJ, Wajngarten M, Bellotti G, Pileggi F,. Nitric oxide inhalation reduces pulmonary tidal volume during exercise in severe chronic heart failure. Am Heart J 1997; 134: 737-744.
40. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, Lewinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E,. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309: 1268-1277.
41. Varma A, Shah KB, Hess ML,. Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation. Congest Heart Fail 2012; 18: 229-233.
42. Rasmussen JG, Toft E, Frøbert O,. Ventricular tachycardia after administration of sildenafil citrate: a case report. J Med Case Rep 2007; 1: 65.
43. Smith WB II, McCaslin IR, Gokce A, Mandava SH, Trost L, Hellstrom WJ,. PDE5 inhibitors: considerations for preference and long-term adherence. Int J Clin Pract 2013; 67: 768-780.
44. Chrysant SG,. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. Curr Hypertens Rep 2013; 15: 475-483.
45. Schäfer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R, Klein M,. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc Res 2009; 82: 30-39.
46. Cooper TJ, Guazzi M, Al-Mohammad A, Amir O, Bengal T, Cleland JG, Dickstein K,. Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. Eur J Heart Fail 2013; 15: 119-122.